CG Oncology Reaches New 52-Week High

Shares of the biopharmaceutical company hit a fresh high as analysts raise price targets

Mar. 10, 2026 at 6:36pm

Got story updates? Submit your updates here. ›

CG Oncology, Inc. (NASDAQ:CGON), a clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers, saw its stock price reach a new 52-week high of $63.89 on Tuesday. The stock closed at $62.62 with trading volume of over 600,000 shares.

Why it matters

CG Oncology's stock surge reflects growing investor optimism about the company's pipeline of immunotherapy candidates. Several Wall Street analysts have recently raised their price targets on the stock, citing the potential of CG Oncology's platform-driven approach to identifying and optimizing antibody therapies for the tumor microenvironment.

The details

CG Oncology's stock price has been on a steady climb in recent months, buoyed by positive clinical data and analyst upgrades. The company's lead candidates are in early-phase trials, and it is collaborating with academic medical centers and contract research organizations to advance its pipeline.

  • CG Oncology's stock reached a new 52-week high of $63.89 on Tuesday, March 10, 2026.
  • The company reported earnings on Friday, February 27, 2026.

The players

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

The Goldman Sachs Group

An investment bank that reiterated a "buy" rating and $82 price target on CG Oncology shares.

Piper Sandler

An investment bank that raised its price target on CG Oncology from $55 to $70 and maintained an "overweight" rating.

Royal Bank of Canada

An investment bank that increased its price target on CG Oncology from $61 to $73 and maintained an "outperform" rating.

HC Wainwright

An investment bank that raised its price target on CG Oncology from $75 to $80 and maintained a "buy" rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.